

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)



(10) International Publication Number
WO 2021/178246 A1

- (51) **International Patent Classification:**
A61K 35/76 (2015.01) *C12N 15/86* (2006.01)
- (21) **International Application Number:**
PCT/US2021/020032
- (22) **International Filing Date:**
26 February 2021 (26.02.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/984,183 02 March 2020 (02.03.2020) US
- (71) **Applicant: TENAYA THERAPEUTICS, INC.** [US/US];
171 Oyster Point Boulevard, Suite 500, South San Francisco,
California 94080 (US).
- (72) **Inventors: LOMBARDI, Laura;** c/o Tenaya Therapeutics,
Inc., 171 Oyster Point Boulevard, Suite 500, South
San Francisco, California 94080 (US). **LEON, Elena C.;** c/
o Tenaya Therapeutics, Inc., 171 Oyster Point Boulevard,
Suite 500, South San Francisco, California 94080 (US). **QURESHI, Tawny Neal;** c/o Tenaya Therapeutics, Inc.,
171 Oyster Point Boulevard, Suite 500, South San Francisco,
California 94080 (US). **IVEY, Kathryn N.;** c/o Tenaya
Therapeutics, Inc., 171 Oyster Point Boulevard, Suite 500,
South San Francisco, California 94080 (US).
- (74) **Agent: WHITTLE, James R.** et al.; Cooley LLP, 1299
Pennsylvania Avenue, NW, Suite 700, Washington, District
of Columbia 20004 (US).
- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** GENE VECTOR CONTROL BY CARDIOMYOCYTE-EXPRESSED MICRORNAS

FIG. 1



(57) **Abstract:** The present disclosure provides vectors and method of use thereof, for cell-type specific repression of expression of transgenes (e.g., cardiomyocyte reprogramming factors) using microRNA binding sites.



WO 2021/178246 A1